Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma
Joselle Cook(Mayo Clinic), Martha Q. Lacy(Mayo Clinic), Thomas E. Witzig(WinnMed), P. Leif Bergsagel(Mayo Clinic in Arizona), Stephen M. Broski, Susan M. Geyer(Mayo Clinic in Florida), David Dingli, Jonas Paludo(WinnMed), Francis K. Buadi, Morie A. Gertz(Medical University of South Carolina), Nelson Leung(WinnMed), Robert A. Kyle(Mayo Clinic), Shaji Kumar(Mayo Clinic), Ronald S. Go(Mayo Clinic), Prashant Kapoor, Amie Fonder, José C. Villasboas(Mayo Clinic), Yi L. Hwa, Baskar Balakrishnan(Tamil University), Marissa Giers(Mayo Clinic), Stephen J. Russell(University of Minnesota Rochester), Bethany Brunton(Mayo Clinic), Rahma Warsame, Stephen M. Ansell(Mayo Clinic), Shruthi Naik(Mayo Clinic), S. Vincent Rajkumar(WinnMed), Wilson I. Gonsalves(Mayo Clinic in Arizona), N. Nora Bennani(Mayo Clinic in Arizona), Mustaqeem Siddiqui(Mayo Clinic in Arizona), Mrinal M. Patnaik(Mayo Clinic), Taxiarchis Kourelis(Mayo Clinic in Arizona), Eli Muchtar(Mayo Clinic), Amylou C. Dueck(Mayo Clinic in Arizona), Nandakumar Packiriswamy(Mayo Clinic in Arizona), Javier Muñoz(The University of Texas MD Anderson Cancer Center), Yi Lin, Lianwen Zhang(University of Minnesota Rochester), Suzanne R. Hayman, Miriam Hobbs, Angela Dispenzieri(Mayo Clinic), Kah Whye Peng(Mayo Clinic), Brenda Ginos(Mayo Clinic in Arizona)
Cited by 44
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k